论文信息 - Warfarin Pharmacogenomics: A big step forward for individualized medicine: enlightened dosing of warfarin - 字舞流文

Warfarin Pharmacogenomics: A big step forward for individualized medicine: enlightened dosing of warfarin

Warfarin Pharmacogenomics: A big step forward for individualized medicine: enlightened dosing of warfarin

Eric J Topol | Darlene J Elias

[1] D. Witt,et al. Effect of a centralized clinical pharmacy anticoagulation service on the outcomes of anticoagulation therapy. , 2005, Chest.

[2] Deborah A Nickerson,et al. Effect of VKORC1 haplotypes on transcriptional regulation and warfarin dose. , 2005, The New England journal of medicine.

[3] B. Horne,et al. Genotypes of the cytochrome p450 isoform, CYP2C9, and the vitamin K epoxide reductase complex subunit 1 conjointly determine stable warfarin dose: a prospective study , 2006, Journal of Thrombosis and Thrombolysis.

[4] J. Hirsh,et al. The pharmacology and management of the vitamin K antagonists: the Seventh ACCP Conference on Antithrombotic and Thrombolytic Therapy. , 2004, Chest.

[5] Deepak Voora,et al. Genetic-based dosing in orthopedic patients beginning warfarin therapy. , 2007, Blood.

[6] David L Veenstra,et al. Association between CYP2C9 genetic variants and anticoagulation-related outcomes during warfarin therapy. , 2002, JAMA.

[7] P. Deloukas,et al. Association of warfarin dose with genes involved in its action and metabolism , 2006, Human Genetics.

[8] F. Kamali,et al. Contribution of age, body size, and CYP2C9 genotype to anticoagulant response to warfarin , 2004, Clinical pharmacology and therapeutics.